1. Scrip
  2. >>R&D

Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail

Otsuka Obtains Global Rights To Two Drugs

 
• By Lisa Takagi

Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.

Sumitomo decided to prioritize other candidates than the four in the Otsuka deal amid financial challenges.
Sumitomo has decided to prioritize other R&D candidates over the four in its Otsuka alliance amid financial challenges • Source: Shutterstock

Amid recent financial challenges and R&D setbacks hitting Sumitomo Pharma Co., Ltd., the mid-sized Japanese firm has decided to prioritize its advanced candidates in oncology, regenerative medicine and the cell therapy area over its struggling assets in the antipsychotic space.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.